Li Wang

Dr. Li Wang

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
LWLi Wang
Li Wang
CXCong Xu
Cong Xu
LXLiu Xia
Liu Xia
YYYang Yang
Yang Yang
LCLu Cao
Lu Cao
YNYun Niu
Yun Niu
Background: The progression of ductal carcinoma in situ (DCIS) into invasive ductal carcinoma (IDC) is prevented by normal breast myoepithelial cells. Studies have suggested that EMT-associated genes were enriched in IDC in contrast to DCIS. This paper explored the relationship and potential mechanism between myoepithelial cells and EMT-associated genes in facilitating the transformation from DCIS to breast cancer. Methods: EMT markers and myoepithelial phenotypic markers in IDC, DCIS, and healthy breast tissue were characterized using immunohistochemical assay. Both in vivo and in vitro models were created to mimic the various cell–cell interactions in the development of invasive breast cancer. Results: We found that EMT markers were more abundant in invasive carcinomas than DCIS and adjacent normal breast tissue. Meanwhile, TGF-β1 regulated the morphology of MCF-7 (epithelial cells substitute) migration and EMT markers during the transformation from DCIS to invasive breast cancer. Additionally, TGF-β1 also regulated invasion, migration and cytokines secretion of MDA-MB-231 (myoepithelial cells substitute) and epithelial cells when co-cultured with MCF-7 both in vitro and in vivo. Conclusions: In conclusion, these findings demonstrated that both EMT phenotypes and cancer-associated myoepithelial cells may have an impact on the development of invasive breast cancer.

17 April 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
LWLi Wang
Li Wang
HYHongyu Yang
Hongyu Yang
LCLu Cao
Lu Cao
YYYang Yang
Yang Yang
RDRan Ding
Ran Ding
Background Defensin beta 1 (DEFB1) is a key immune response gene, but its role in cancer remains unclear. This study aims to explore DEFB1 expression, genetic alterations, immune infiltration, and prognostic significance across various cancer types. Methods We analyzed DEFB1 expression and its association with cancer prognosis using data from public platforms, including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Human Protein Atlas (HPA). Additionally, we examined DEFB1 genetic alterations, immune cell infiltration, and its molecular partners using various bioinformatics tools. Results DEFB1 expression was highest in salivary glands, kidneys, and pancreas. In cancers, DEFB1 was upregulated in cholangiocarcinoma, kidney chromophobe, and melanoma, but downregulated in breast, colon, and rectal cancers. High DEFB1 expression was linked to poorer overall survival in lung adenocarcinoma and pancreatic adenocarcinoma, but better survival in head and neck squamous cell carcinoma. Genetic analysis revealed alterations in liver and gastric cancers. Immune infiltration analysis showed a correlation between DEFB1 and cancer-associated fibroblasts in liver cancer, while neutrophil infiltration was linked to bladder carcinoma, diffuse large B-cell lymphoma, and lung squamous cell carcinoma. Key genes associated with DEFB1 included KLK1, BSND, and CLCNKB. Discussion This study highlights DEFB1’s potential as a prognostic biomarker and its influence on the tumor immune microenvironment across different cancers. These findings suggest DEFB1 could be a target for future cancer therapies, although further studies are needed to validate these results.

22 February 2024 in Aging
Verified
Journal Article
Open access
PDF file
LWLi Wang
Li Wang
MLMenghan Li
Menghan Li
HYHongyu Yang
Hongyu Yang
FDFenghuan Dai
Fenghuan Dai
NXNing Xie
Ning Xie
RDRan Ding
Ran Ding
Background: Breast cancer (BC) is a heterogeneous tumor with a variety of etiology and clinical features. Antibody-dependent cell phagocytosis (ADCP) is the last step of immune checkpoint inhibition (ICI), and macrophages detect and recognize tumor cells, then destroy and engulf tumor cells. Despite the large number, negative regulators that inhibit phagocytic activity are still a key obstacle to the full efficacy of ICI. Patients and methods: An ADCP-related risk score prognostic model for risk stratification as well as prognosis prediction was established in the Cancer Genome Atlas (TCGA) cohort. The predictive value of ADCP risk score in prognosis and immunotherapy was also further validated in the TCGA along with International Cancer Genome Consortium cohorts. To promote the clinical application of the risk score, a nomogram was established, with its effectiveness verified by different methods. Results: In this study, the genes collected from previous studies were defined as ADCP-related genes. In BC patients, two ADCP-related subtypes were identified. The immune characteristics and prognostic stratification were significant different between them. Conclusions: We identified two subtypes associated with ADCP gene expression in breast cancer. They have significant differences in immune cells, molecular functions, HLA family genes, immune scores, stromal scores, and inflammatory gene expression, which have important guiding significance for the selection of clinical treatment methods. At the same time, we constructed a risk model based on ADCP, and the risk score can be used as a good indicator of prognosis, providing potential therapeutic advantages for chemotherapy and immunotherapy, thus helping the clinical decision-making of BC patients.

15 August 2023 in Research Square
Verified
Preprint
Open access
PDF file
LWLi Wang
Li Wang
MLMenghan Li
Menghan Li
HYHongyu Yang
Hongyu Yang
FDFenghuan Dai
Fenghuan Dai
NXNing Xie
Ning Xie
RDRan Ding
Ran Ding
Background Breast cancer (BC) is a heterogeneous tumor with a variety of etiology and clinical features. Antibody-dependent cell phagocytosis (ADCP) is the last step of immune checkpoint inhibition (ICI), and macrophages destroy tumor cells after previous recognition activation. Despite the large number, negative regulators that inhibit phagocytic activity are still a key obstacle to the full efficacy of ICI. Patients and methods: An ADCP -related risk score prognostic model for risk stratification as well as prognosis prediction was established in the Cancer Genome Atlas (TCGA) cohort. The predictive value of ADCP risk score in prognosis and immunotherapy was also further validated in the TCGA along with International Cancer Genome Consortium cohorts. To promote the clinical application of the risk score, a nomogram was established, with its effectiveness verified by different methods. Results In this study, the genes collected from previous studies were defined as ADCP-related genes. In BC patients, two ADCP-related subtypes were identified. The immune characteristics and prognostic stratification were significant different between them. Conclusion Based on these findings, it can be inferred that there is a significant relationship between ADCP and TME (tumor microenvironment) in BC. Risk score could be used as a good indicator for prognosis, potential in providing therapeutic advantages for chemotherapy as well as immunotherapy, thereby aiding in the clinical decision-making process for BC patients.

2 August 2024 in Research Square
Verified
Preprint
Open access
PDF file
LWLi Wang
Li Wang
HYHongyu Yang
Hongyu Yang
LCLu Cao
Lu Cao
YYYang Yang
Yang Yang
RDRan Ding
Ran Ding
Despite many cell or animal experiments that support the close association of DEFB1 with cancer, no comprehensive pan-cancer analysis has been reported. The present research initially investigated its role in many cancers using The Cancer Genome Atlas (TCGA) data. To analyze DEFB1 in cancers, we utilized The Human Protein Atlas (HPA), TCGA, Genotype-Tissue Expression (GTEx), Tumor Immune Estimation Resource 2.0 (TIMER2.0), University of Alabama at Birmingham Cancer data analysis Portal (UALCAN), Gene Expression Profiling Interactive Analysis 2 (GEPIA2), and cBioPortal databases. The visualization of data was primarily accomplished through the use of the R language. Most cancers and their adjacent normal tissues exhibit differential expression of DEFB1.The prognosis of distinct cancers was notably impacted by DEFB1. High DEFB1 expression could induce a poorer overall survival (OS) in the lung adenocarcinoma (LUAD)and pancreatic adenocarcinoma (PAAD) cohorts; in contrast, it could lead to a significantly higher OS in the head-neck squamous cell carcinoma (HNSC) cohort (P < 0.05). Moreover, high DEFB1 expression could result in a poor disease-free survival (DFS) in the cholangiocarcinoma (CHOL) cohort (P < 0.05). Notably, Liver hepatocellular carcinoma (LIHC)samples demonstrated the highest DEFB1 mutation frequency among all cancer types. Furthermore, there was a close relationship of DEFB1 expression with the extent of cancer-associated fibroblast infiltration in LIHC, thyroid carcinoma (THCA), colon adenocarcinoma (COAD), head-neck squamous cell carcinoma (HNSC), and stomach adenocarcinoma (STAD), while neutrophil infiltration was revealed in other malignancies, including bladder carcinoma (BLCA), diffuse large B-cell (DLBC), lung squamous cell carcinoma (LUSC), PAAD, as well as uterine corpus endometrial carcinoma (UCEC). This initial pan-cancer research can help comprehensively understand the carcinogenesis of DEFB1 in many malignancies.